Improved survival in patients ≥60 with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 valor study Meeting Abstract

   


Authors: Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M. D.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Cortes, J.; Roboz, G. J.; Craig, A. R.; Fox, J. A.; Ward, R.; Smith, J. A.; Acton, G.; Mehta, C.; Kantarjian, H. M.; Stuart, R. K.
Abstract Title: Improved survival in patients ≥60 with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 valor study
Meeting Title: 20th Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 100
Issue: Suppl. 1
Meeting Dates: 2015 Jun 11-14
Meeting Location: Vienna, Austria
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2015-06-01
Start Page: 46
End Page: 47
Language: English
ACCESSION: WOS:000361204901097
PROVIDER: wos
PMCID: PMC4480587
Notes: Meeting Abstract: P197 -- Source: Wos